Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities

Drug Metabolism and Disposition

Volumn 32, Issue 8, 2004, Pages 821-827

  Li, Xue Qing ^a   Andersson, Tommy B ^a   Ahlström, Marie ^a   Weidolf, Lars ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4' HYDROXYMEPHENYTOIN; BENZIMIDAZOLE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DICLOFENAC; ESOMEPRAZOLE; LANSOPRAZOLE; MIDAZOLAM; OMEPRAZOLE; OMEPRAZOLE DERIVATIVE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RABEPRAZOLE THIOETHER; SULFIDE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; COMPETITIVE INHIBITION; DRUG CLEARANCE; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; ENANTIOMER; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; IN VITRO STUDY; ISOMERISM; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; BENZIMIDAZOLES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; LIVER; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES;

EID: 3242676832     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.8.821     Document Type: Article

References (40)

1. Äbelö A, Andersson T, Antonsson M, Naudot A, Skanberg I, and Weidolf L (2000) Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 28:966-972.
2. Andersson T (1991) Omeprazole drug interaction studies. Clin Pharmacokinet 21:195-212.
3. Andersson T (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 31:9-28.
4. Andersson T, Cederberg C, Edvardsson G, Heggelund A, and Lundborg P (1990) Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 47:79-85.
5. Andersson T, Hassan-Alin M, Hasselgren G, and Röhss K (2001a) Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 40:523-537.
6. Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, and Weidolf L (2001b) Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 40:411-426.
7. Andersson T, Holmberg J, Röhss K, and Walan A (1998) Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole and pantoprazole. Br J Clin Pharmacol 45:369-375.
8. Andersson T, Miners J, Veronese M, Tassaneeyakul W, Tassaneeyakul W, Meyer U, and Birkett D (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36:521-530.
9. Cavanaugh J, Winters E, Cohen A, Locke C, and Braeckman R (1991) Lack of effect of lansoprazole on steady state warfarin metabolism. Gastroenterology 100:A40.
10. Chong E and Ensom M (2003) Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 23:460-471.
11. Ernster L, Siekevitz P, and Palada G (1962) Enzyme-structure relationships in the endoplasmic reticulum of rat liver. J Cell Biol 15:541-562.
12. Fuhr U and Jetter A (2002) Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 57:595-601.
13. Furuta S, Kamada E, Suzuki T, Sugimoto T, Kawabata Y, Shinozaki Y, and Sano H (2001) Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica 31:1-10.
14. Gerson L and Triadafilopoulos G (2001) Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 13:611-616.
15. Gugler R, Hartmann M, Rudi J, Brod I, Huber R, Steinijans V, Bliesath H, Wurst W, and Klotz U (1996) Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br J Clin Pharmacol 42:249-252.
16. Gugler R and Jensen J (1985) Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 89:1235-1241.
17. Hassan-Alin M, Andersson T, Bredberg E, and Röhss K (2000) Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 56:665-670.
18. Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M, Morisawa T, Fukushima Y, Nakagawa K, Hasegawa J, et al. (2001) Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Clin Pharmacol 57:485-492.
19. Ishizaki T, Chiba K, Manabe K, Koyama E, Hayashi M, Yasuda S, Horai Y, Tomono Y, Yamato C, and Toyoki T (1995) Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther 58:155-164.
20. Jungnickel P (2000) Pantoprazole: a new proton pump inhibitor. Clin Ther 22:1268-1293.
21. Ko J, Sukhova N, Thacker D, Chen P, and Flockhart D (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853-862.
22. Lefebvre R, Flouvat B, Karolac-Tamisier S, Moerman E, and Van Ganse E (1992) Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 52:458-463.
23. Lindberg P, Keeling D, Fryklund J, Andersson T, Lundborg P, and Carlsson E (2003) Review article: esomeprazole-enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion. Aliment Pharmacol Ther 17:481-488.
24. Lowry O, Rosebrough N, Farr A, and Randall R (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
25. McColl K and Kennerley P (2002) Proton pump inhibitors-differences emerge in hepatic metabolism. Dig Liver Dis 34:461-467.
26. Papp-Jambor C, Jaschinski U, and Forst H (2002) Cytochrome P450 enzymes and their role in drug interactions. Anaesthesist 51:2-15.
27. Pearce R, Rodrigues A, Goldstein J, and Parkinson A (1996) Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277:805-816.
28. Pichard-Garcia L, Whomsley R, Daujat M, Maurel P, Setoyama T, and Humphries T (2000) Comparative effects of rabeprazole and omeprazole on the inducibility of cytochrome P450-1A and cytochrome P450-3A isoenzymes in human hepatocytes and effects on cyclosporin metabolism in human liver microsomes. Clin Drug Investig 20:245-254.
29. Röhss K, Wilder Smith C, Claar Nilsson C, Lundin C, and Hasselgren G (2002) Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors (Abstract P.A.090). J Gastroenterol Hepatol 17 (Suppl S):A228.
30. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, et al. (2001) Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 15:1929-1937.
31. Sohn D, Kwon J, and Kim H (1996) Influence of S-mephenytoin phenotype on lansoprazole metabolism. Clin Pharmacol Ther 59:137.
32. Sohn D, Kwon J, Kim H, and Ishizaki T (1997) Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin Pharmacol Ther 61:574-582.
33. Steinijans V, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, and Radtke H (1997) An updated review of pantoprazole drug interactions in man. Verdauungskrankheiten 15:77-96.
34. Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, Ryokawa Y, Hakusui H, Yamamori S, and Ishizaki T (1997) Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype. Clin Pharmacol Ther 62:619-628.
35. Tanaka M, Yamazaki H, Ryokawa Y, Hakusui H, Nakamichi N, and Sekino H (1996) Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers. Int J Clin Pharmacol Ther 34:415-419.
36. Tucker G (1994) The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 8:33-38.
37. VandenBranden M, Ring B, Binkley S, and Wrighton S (1996) Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 6:81-91.
38. Vanderhoff B and Tahboub R (2002) Proton pump inhibitors: an update. Am Fam Physician 66:273-280.
39. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, and Ishizaki T (1995) Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 58:143-154.
40. Zumbrunnen T and Jann M (1998) Drug interactions with antipsychotic agents incidence and therapeutic implications. CNS Drugs 9:381-401.